Sodium–glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions

OBJECTIVE: To evaluate whether adverse event reports to the US Food and Drug Administration on incidents of ketoacidosis from use of sodium glucose cotransport inhibitors (SGLT2 inhibitors) provide insight into ways this new class of drugs is being prescribed with other antihyperglycemic agents; to...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Elia, John A, Segal, Alissa R, Bayliss, George P, Weinrauch, Larry A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479258/
https://www.ncbi.nlm.nih.gov/pubmed/28670136
http://dx.doi.org/10.2147/IJNRD.S135899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479258/
https://www.ncbi.nlm.nih.gov/pubmed/28670136
http://dx.doi.org/10.2147/IJNRD.S135899

Ejemplares similares